— Know what they know.
Not Investment Advice
Also trades as: FYB.DE (XETRA) · $vol 0M

0W4N.L LSE

Formycon AG
1W: +0.6% 1M: -1.2% 3M: -2.2% YTD: -17.9% 1Y: -22.7% 3Y: -66.5%
€19.10 ($21.40)
-0.08 (-0.42%)
 
Weekly Expected Move ±2.3%
€18 €19 €19 €20 €20
LSE · Healthcare · Biotechnology · Tech Score Sell · Power 42 · €339.0M mcap · 13M float · 0.0034% daily turnover

Income Trends

Revenue
$70M -10.3% ▼
5Y CAGR: +16.0%
Gross Profit
$15M -36.3% ▼
5Y CAGR: +72.8%
Operating Income
-$24M -6280.2% ▼
Net Income
-$126M -265.8% ▼
EPS (Diluted)
$-7.18 -252.1% ▼
EBITDA
-$4M -105.1% ▼

Profit Margins

Year-over-Year Growth

View Full Income Statement
Line ItemFY2020FY2021FY2022FY2023FY2024
Revenue$34M$37M$42M$78M$70M
YoY Growth+3.2%+7.0%+16.1%+82.8%-10.3%
Cost of Revenue$36M$27M$30M$54M$55M
Gross Profit-$2M$10M$12M$23M$15M
Gross Margin-6.4%27.6%28.4%30.0%21.3%
R&D Expenses$41M$17M$17M$9M$17M
SG&A Expenses$6M$7M$13M$15M$21M
Operating Expenses$14M$24M$30M$24M$38M
Operating Income-$7M-$14M-$18M-$369K-$24M
Operating Margin-19.1%-37.8%-41.7%-0.5%-33.8%
Interest Expense$0$173K$143K$94K$1M
Income Before Tax-$7M-$14M$37M$79M-$144M
Tax Expense$85K-$917K$604K$3M-$19M
Net Income-$7M-$13M$36M$76M-$126M
Net Margin-19.7%-36.3%84.7%97.6%-180.4%
EPS (Diluted)$-0.66$-1.20$2.59$4.72$-7.18
EBITDA-$6M-$12M$52M$81M-$4M
Shares Outstanding11M11M14M16M17M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms